{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:18:38Z","timestamp":1791389918393,"version":"4.3.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T00:00:00Z","timestamp":1510876800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s10067-017-3916-y","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T07:48:53Z","timestamp":1510904933000},"page":"2391-2397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol"],"prefix":"10.1007","volume":"37","author":[{"given":"Alina","family":"Soare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1292-2964","authenticated-orcid":false,"given":"Ana Maria","family":"Gheorghiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Aram\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drago\u0219","family":"Bumb\u0103cea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rucsandra","family":"Dobrot\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raida","family":"Onea\u0163\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Pintilie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Milicescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioan","family":"Ancu\u0163a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Sasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ciofu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liviu","family":"Macovei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Stoica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Bojinc\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Mihai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,17]]},"reference":[{"issue":"178","key":"3916_CR1","first-page":"283","volume":"30","author":"J Swierkot","year":"2011","unstructured":"Swierkot J, Madej M (2011) The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part I. Tumor necrosis factor alpha inhibitors. Polski merkuriusz lekarski: Organ Polskiego Towarzystwa Lekarskiego 30(178):283\u2013288","journal-title":"Polski merkuriusz lekarski: Organ Polskiego Towarzystwa Lekarskiego"},{"issue":"12","key":"3916_CR2","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.3899\/jrheum.150384","volume":"42","author":"G Haugeberg","year":"2015","unstructured":"Haugeberg G, Boyesen P, Helgetveit K, Proven A (2015) Clinical and radiographic outcomes in patients diagnosed with early rheumatoid arthritis in the first years of the biologic treatment era: a 10-year prospective observational study. J Rheumatol 42(12):2279\u20132287. \nhttps:\/\/doi.org\/10.3899\/jrheum.150384","journal-title":"J Rheumatol"},{"key":"3916_CR3","doi-asserted-by":"publisher","first-page":"CD005468","DOI":"10.1002\/14651858.CD005468.pub2","volume":"4","author":"LJ Maxwell","year":"2015","unstructured":"Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P, Wells GA (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 4:CD005468. \nhttps:\/\/doi.org\/10.1002\/14651858.CD005468.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"3916_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.rdc.2015.07.010","volume":"41","author":"PJ Mease","year":"2015","unstructured":"Mease PJ (2015) Biologic therapy for psoriatic arthritis. Rheum Dis Clin N Am 41(4):723\u2013738. \nhttps:\/\/doi.org\/10.1016\/j.rdc.2015.07.010","journal-title":"Rheum Dis Clin N Am"},{"issue":"1","key":"3916_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/annrheumdis-2011-200690","volume":"72","author":"KL Winthrop","year":"2013","unstructured":"Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR, Baddley JW, McFarland B, Austin D, Radcliffe L, Suhler E, Choi D, Rosenbaum JT, Herrinton LJ (2013) Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis 72(1):37\u201342. \nhttps:\/\/doi.org\/10.1136\/annrheumdis-2011-200690","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"3916_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.rdc.2012.08.019","volume":"38","author":"KL Winthrop","year":"2012","unstructured":"Winthrop KL (2012) Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention. Rheum Dis Clin N Am 38(4):727\u2013745. \nhttps:\/\/doi.org\/10.1016\/j.rdc.2012.08.019","journal-title":"Rheum Dis Clin N Am"},{"issue":"10","key":"3916_CR7","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1164\/rccm.201405-0967OC","volume":"190","author":"M Sester","year":"2014","unstructured":"Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, Dominguez J, Duarte R, Ernst M, Eyuboglu FO, Gerogianni I, Girardi E, Goletti D, Janssens JP, Julander I, Lange B, Latorre I, Losi M, Markova R, Matteelli A, Milburn H, Ravn P, Scholman T, Soccal PM, Straub M, Wagner D, Wolf T, Yalcin A, Lange C, TBNET (2014) Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 190(10):1168\u20131176. \nhttps:\/\/doi.org\/10.1164\/rccm.201405-0967OC","journal-title":"Am J Respir Crit Care Med"},{"key":"3916_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1183\/1025448x.erm5812","volume":"58","author":"M Sester","year":"2012","unstructured":"Sester M, Bumbacea D, Duarte R, Lange C (2012) TB in the immunocompromised host. Eur Respir Soc Monogr 58:230\u2013241. \nhttps:\/\/doi.org\/10.1183\/1025448x.erm5812","journal-title":"Eur Respir Soc Monogr"},{"issue":"3","key":"3916_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.jaad.2015.06.004","volume":"73","author":"CS Ahn","year":"2015","unstructured":"Ahn CS, Dothard EH, Garner ML, Feldman SR, Huang WW (2015) To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis. J Am Acad Dermatol 73(3):420\u2013428 e421. \nhttps:\/\/doi.org\/10.1016\/j.jaad.2015.06.004","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3916_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/2229-5178.93479","volume":"3","author":"S Nayak","year":"2012","unstructured":"Nayak S, Acharjya B (2012) Mantoux test and its interpretation. Indian Dermatol Online J 3(1):2\u20136. \nhttps:\/\/doi.org\/10.4103\/2229-5178.93479","journal-title":"Indian Dermatol Online J"},{"issue":"1","key":"3916_CR11","first-page":"20","volume":"5","author":"C Cojocaru","year":"2010","unstructured":"Cojocaru C, Panescu M, Vasilescu C, Mihaescu T (2010) Comparative study using tuberculin from Cantacuzino institute versus Statens serum institute. Maedica 5(1):20\u201323","journal-title":"Maedica"},{"key":"3916_CR12","doi-asserted-by":"publisher","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement (2000) Am J Respir Crit Care Med 161(4 Pt 2):S221\u2013247. \nhttps:\/\/doi.org\/10.1164\/ajrccm.161.supplement_3.ats600","DOI":"10.1164\/ajrccm.161.supplement_3.ats600"},{"issue":"3\/4","key":"3916_CR13","first-page":"267","volume":"19","author":"D Bumbacea","year":"2011","unstructured":"Bumbacea D, Lungu R, Pele I, Neagu A, Alexiu I, Ecomomescu MC, Bumbacea S, Diaconu CC (2011) New immunodiagnostic tests for latent and active tuberculosis. Rom J Lab Med 19(3\/4):267\u2013278","journal-title":"Rom J Lab Med"},{"issue":"RR-5","key":"3916_CR14","first-page":"1","volume":"59","author":"GH Mazurek","year":"2010","unstructured":"Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, Committee IE, Centers for Disease C, Prevention (2010) Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection\u2014United States, 2010. MMWR Recomm Rep 59(RR-5):1\u201325","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"3916_CR15","first-page":"12","volume":"63","author":"GG Popescu","year":"2014","unstructured":"Popescu GG, Spinu V, Chiotan DI (2014) Aspects of TB endemia in Romania and the response of the National Programme for Prevention, Surveillance and Control of Tuberculosis. Pneumologia 63(1):12\u201314 16-18","journal-title":"Pneumologia"},{"key":"3916_CR16","volume-title":"IBM SPSS Statistics for Macintosch, Version 20.0","author":"IBM Corp. Released","year":"2011","unstructured":"IBM Corp. Released (2011) IBM SPSS Statistics for Macintosch, Version 20.0. IBM Corp, Armonk"},{"key":"3916_CR17","unstructured":"Open Source Epidemiologic Statistics for Public Health application (\nhttp:\/\/openepi.com\n\n)"},{"issue":"12","key":"3916_CR18","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1136\/ard.2008.102103","volume":"68","author":"GR Burmester","year":"2009","unstructured":"Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL (2009) Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 68(12):1863\u20131869. \nhttps:\/\/doi.org\/10.1136\/ard.2008.102103","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3916_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1468-3083.2010.03836.x","volume":"25","author":"AI Sanchez-Moya","year":"2011","unstructured":"Sanchez-Moya AI, Dauden E (2011) Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients. J Eur Acad Dermatol Venereol: JEADV 25(6):730\u2013733. \nhttps:\/\/doi.org\/10.1111\/j.1468-3083.2010.03836.x","journal-title":"J Eur Acad Dermatol Venereol: JEADV"},{"issue":"1","key":"3916_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5114\/aoms.2013.33352","volume":"9","author":"J Paluch-Oles","year":"2013","unstructured":"Paluch-Oles J, Magrys A, Koziol-Montewka M, Koszarny A, Majdan M (2013) Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-alpha agents. Arch Med Sci: AMS 9(1):112\u2013117. \nhttps:\/\/doi.org\/10.5114\/aoms.2013.33352","journal-title":"Arch Med Sci: AMS"},{"issue":"10","key":"3916_CR21","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.5588\/ijtld.12.0111","volume":"16","author":"N Saidenberg-Kermanac\u2019h","year":"2012","unstructured":"Saidenberg-Kermanac\u2019h N, Semerano L, Naccache JM, Brauner M, Falgarone G, Dumont-Fischer D, Guillot X, Valeyre D, Boissier MC (2012) Screening for latent tuberculosis in anti-TNF-alpha candidate patients in a high tuberculosis incidence setting. Int J Tuberc Lung Dis 16(10):1307\u20131314. \nhttps:\/\/doi.org\/10.5588\/ijtld.12.0111","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"3916_CR22","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1097\/MIB.0b013e31829f008f","volume":"19","author":"A Swaminath","year":"2013","unstructured":"Swaminath A, Bhadelia N, Wang YC (2013) Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease. Inflamm Bowel Dis 19(11):2444\u20132449. \nhttps:\/\/doi.org\/10.1097\/MIB.0b013e31829f008f","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"3916_CR23","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3899\/jrheum.150057","volume":"42","author":"JW Ai","year":"2015","unstructured":"Ai JW, Zhang S, Ruan QL, YQ Y, Zhang BY, Liu QH, Zhang WH (2015) The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-alpha antagonist: a metaanalysis of both randomized controlled trials and registry\/cohort studies. J Rheumatol 42(12):2229\u20132237. \nhttps:\/\/doi.org\/10.3899\/jrheum.150057","journal-title":"J Rheumatol"},{"issue":"8","key":"3916_CR24","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/acr.22815","volume":"68","author":"RJ Desai","year":"2016","unstructured":"Desai RJ, Thaler KJ, Mahlknecht P, Gartlehner G, McDonagh MS, Mesgarpour B, Mazinanian A, Glechner A, Gopalakrishnan C, Hansen RA (2016) Comparative risk of harm associated with the use of targeted immunomodulators: a systematic review. Arthritis Care Res 68(8):1078\u20131088. \nhttps:\/\/doi.org\/10.1002\/acr.22815","journal-title":"Arthritis Care Res"},{"issue":"3","key":"3916_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/ard.2009.118935","volume":"69","author":"WG Dixon","year":"2010","unstructured":"Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, Consortium BSRBRCC, Symmons DP, Register BSRB (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69(3):522\u2013528. \nhttps:\/\/doi.org\/10.1136\/ard.2009.118935","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3916_CR26","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3899\/jrheum.150177","volume":"43","author":"B Kisacik","year":"2016","unstructured":"Kisacik B, Pamuk ON, Onat AM, Erer SB, Hatemi G, Ozguler Y, Pehlivan Y, Kilic L, Ertenli I, Can M, Direskeneli H, Keser G, Oksel F, Dalkilic E, Yilmaz S, Pay S, Balkarli A, Cobankara V, Cetin GY, Sayarlioglu M, Cefle A, Yazici A, Avci AB, Terzioglu E, Ozbek S, Akar S, Gul A (2016) Characteristics predicting tuberculosis risk under tumor necrosis factor-alpha inhibitors: report from a large multicenter cohort with high background prevalence. J Rheumatol 43(3):524\u2013529. \nhttps:\/\/doi.org\/10.3899\/jrheum.150177","journal-title":"J Rheumatol"},{"issue":"3","key":"3916_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000434684","volume":"90","author":"S Borekci","year":"2015","unstructured":"Borekci S, Atahan E, Demir Yilmaz D, Mazican N, Duman B, Ozguler Y, Musellim B, Hamuryudan V, Ongen G (2015) Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-alpha treatment. Respiration 90(3):191\u2013198. \nhttps:\/\/doi.org\/10.1159\/000434684","journal-title":"Respiration"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-017-3916-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3916-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-017-3916-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,15]],"date-time":"2018-08-15T02:52:36Z","timestamp":1534301556000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-017-3916-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,17]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["3916"],"URL":"https:\/\/doi.org\/10.1007\/s10067-017-3916-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,17]]}}}